Le Figaro. - You have just announced your new strategy to combat Sars-CoV-2 variants. What is it exactly?
Dan Staner, Head of Moderna in Europe, Africa and the Middle East. -
Everything starts from the observation that the virus continues to spread and that many mutations have appeared, some of which are more transmissible.
These may or may be problematic for first-generation vaccines, developed from the virus identified in Wuhan, which was the only one known when we started manufacturing our vaccine.
From now on, our strategy is oriented on the one hand towards the development of vaccine booster shots, intended for people who will have already received two doses of our vaccine this year, and on the other hand the manufacture of new vaccines.
We want to act on both levels.
What will these boosters and vaccines consist of?
For recalls, we will be working on three options.
The first will simply be an injection containing
This article is for subscribers only.
You have 85% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in
